Ganfeng Lithium Co., Limited (1772.HK)
HKD 20.45
(-2.39%)
HKD 20.45
(-2.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.91 Billion CNY | -66.22% |
| 2022 | 23.68 Billion CNY | 283.04% |
| 2021 | 6.4 Billion CNY | 388.64% |
| 2020 | 1.27 Billion CNY | -8.92% |
| 2019 | 910.27 Million CNY | -24.47% |
| 2018 | 1.65 Billion CNY | -3.16% |
| 2017 | 1.85 Billion CNY | 114.19% |
| 2016 | 646.26 Million CNY | 221.93% |
| 2015 | 248.54 Million CNY | 61.48% |
| 2014 | 167.16 Million CNY | 26.78% |
| 2013 | 128.78 Million CNY | 7.82% |
| 2012 | 115.22 Million CNY | 31.31% |
| 2011 | 92.17 Million CNY | 39.12% |
| 2010 | 68.53 Million CNY | 6.62% |
| 2009 | 63.39 Million CNY | -10.64% |
| 2008 | 70.66 Million CNY | 36.53% |
| 2007 | 52.3 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 102.45 Million CNY | 111.92% |
| 2024 Q2 | 338.17 Million CNY | 230.06% |
| 2023 Q4 | -84.89 Million CNY | 48.37% |
| 2023 FY | - CNY | -66.22% |
| 2023 Q1 | 3.57 Billion CNY | -43.28% |
| 2023 Q2 | 3.85 Billion CNY | 7.9% |
| 2023 Q3 | -164.41 Million CNY | -104.27% |
| 2022 Q4 | 6.29 Billion CNY | -24.28% |
| 2022 FY | - CNY | 283.04% |
| 2022 Q1 | 3.62 Billion CNY | -5.08% |
| 2022 Q2 | 5.08 Billion CNY | 40.07% |
| 2022 Q3 | 8.31 Billion CNY | 63.66% |
| 2021 Q3 | 781.68 Million CNY | -6.1% |
| 2021 Q4 | 3.82 Billion CNY | 388.91% |
| 2021 FY | - CNY | 388.64% |
| 2021 Q1 | 416.91 Million CNY | 47.76% |
| 2021 Q2 | 832.5 Million CNY | 99.68% |
| 2020 Q3 | 257.52 Million CNY | -10.69% |
| 2020 Q2 | 288.34 Million CNY | 66.67% |
| 2020 Q1 | 172.99 Million CNY | -39.11% |
| 2020 FY | - CNY | -8.92% |
| 2020 Q4 | 282.15 Million CNY | 9.56% |
| 2019 Q1 | 267.63 Million CNY | -28.19% |
| 2019 Q4 | 284.14 Million CNY | 6.17% |
| 2019 Q3 | 267.63 Million CNY | -22.91% |
| 2019 FY | - CNY | -24.47% |
| 2019 Q2 | 347.18 Million CNY | 29.73% |
| 2018 Q1 | 429.47 Million CNY | -49.04% |
| 2018 Q4 | 372.71 Million CNY | 7.66% |
| 2018 FY | - CNY | -3.16% |
| 2018 Q3 | 346.2 Million CNY | -37.76% |
| 2018 Q2 | 556.24 Million CNY | 29.52% |
| 2017 Q1 | 171.6 Million CNY | 1.09% |
| 2017 FY | - CNY | 114.19% |
| 2017 Q4 | 842.78 Million CNY | 83.56% |
| 2017 Q3 | 459.12 Million CNY | -12.42% |
| 2017 Q2 | 524.23 Million CNY | 205.49% |
| 2016 FY | - CNY | 221.93% |
| 2016 Q4 | 169.74 Million CNY | -24.04% |
| 2016 Q3 | 223.47 Million CNY | 13.79% |
| 2016 Q1 | 155.99 Million CNY | 73.88% |
| 2016 Q2 | 196.38 Million CNY | 25.9% |
| 2015 Q4 | 89.71 Million CNY | 108.15% |
| 2015 Q1 | 30.2 Million CNY | -29.67% |
| 2015 Q2 | 41.37 Million CNY | 36.95% |
| 2015 Q3 | 43.09 Million CNY | 4.18% |
| 2015 FY | - CNY | 61.48% |
| 2014 Q1 | 25.46 Million CNY | -41.78% |
| 2014 Q4 | 42.94 Million CNY | 93.83% |
| 2014 Q3 | 22.15 Million CNY | -14.57% |
| 2014 Q2 | 25.93 Million CNY | 1.84% |
| 2014 FY | - CNY | 26.78% |
| 2013 Q3 | 16.88 Million CNY | -34.21% |
| 2013 FY | - CNY | 7.82% |
| 2013 Q1 | 18.99 Million CNY | -49.39% |
| 2013 Q2 | 25.67 Million CNY | 35.15% |
| 2013 Q4 | 43.74 Million CNY | 159.01% |
| 2012 Q3 | 19.79 Million CNY | 27.48% |
| 2012 FY | - CNY | 31.31% |
| 2012 Q1 | 19.23 Million CNY | -25.67% |
| 2012 Q2 | 15.52 Million CNY | -19.3% |
| 2012 Q4 | 37.52 Million CNY | 89.61% |
| 2011 Q2 | 14.12 Million CNY | -4.34% |
| 2011 FY | - CNY | 39.12% |
| 2011 Q4 | 25.88 Million CNY | 94.15% |
| 2011 Q3 | 13.33 Million CNY | -5.64% |
| 2011 Q1 | 14.77 Million CNY | -5.02% |
| 2010 Q1 | 14.4 Million CNY | -30.54% |
| 2010 FY | - CNY | 6.62% |
| 2010 Q4 | 15.55 Million CNY | 50.69% |
| 2010 Q3 | 10.31 Million CNY | -26.9% |
| 2010 Q2 | 14.11 Million CNY | -2.01% |
| 2009 Q3 | 12.81 Million CNY | 0.0% |
| 2009 Q4 | 20.74 Million CNY | 61.91% |
| 2009 FY | - CNY | -10.64% |
| 2008 FY | - CNY | 36.53% |
| 2007 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Wai Chun Bio-Technology Limited | 14.89 Million HKD | -46334.338% |
| Lee & Man Chemical Company Limited | 597.01 Million HKD | -1058.337% |